covance 050218 AVCT… XXXX By Malcolm Stacey | Thursday 30 January 2020 Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article. Hello, Share Speakers. If you’d acted on my Avacta (AVCT) commendation yesterday you’d be up by nearly 20% already. But I still think there’s a chance to make some more on this interesting share. What I didn’t have time to analyse yesterday was the latest trading update – which makes jolly reading… Numbers from just over a week ago showed a strong revenue growth and cash position. They covered a 17-month period to the end of 2019. Revenues including an initial payment from L G Chee increased to £5 million, ahead of market expectations. Importantly, revenues from Avacta’s diagnostics business have grown by 130% as more customer evaluations of its Affimer projects are underway (affimers are the company’s substitute for antibodies). The company says its sales pipeline into 2020 is the strongest to date. The cash position, always so important to the more cautious among us, is perky. Cash on December 31 stood at £8.7 million, following a placing in November. The company expects even better things when it takes its new drug AVA6000 into the clinic in the second half of 2020. This drug is a re-engineered form of the chemotherapy Doxorubicin, an effective cancer treatment. It has been modified with the aim of reducing side effects. Results are expected before the end of the year. The group’s revenues this year will also benefit from a new collaboration with ADC Therapeutics and the recently announced joint venture with Daewoong Pharmaceuticals; each of which will fully fund Avacta’s related research and development. Now it has to be admitted that Avacta has had a troubled share life. But the shaky times seem behind the company now. And the depressed share price, so galvanised lately, now seems set to improve even more. See you in the Punter’s Return?
covance 050218 AVCT… XXXX Back to November 2019 high turner pope often pushing it. 23p equal to were i last topped up.
covance 050218 AVCT… XXXX Fell to lows of 15.25p 6th November 2019… spike up yesterday 7th Nov 20% to 17p
covance 050218 AVCT… XXXX Keeps falling but still above my previous top up .
covance 050218 AVCT… XXXX Marked down 10% this morning and news of it , must all be in spread as still 34p . Poor RNS the reason .
covance 050218 AVCT… XXXX Dropped back down last month from high of 45p … now 34p
Avacta presentation at ShareSoc 13.3.19 Avacta presentation at ShareSoc London 13.3.19 by Dr Alastair Smith [link] Dr Smith gives a comprehensive overview of AVCT, followed by the Q&A.
3% Shareholders Significant Shareholdings Current significant shareholders are as follows: IP Group plc – 17.16% J O Hambro – 10.91% Baillie Gifford & Co Limited – 8.54% Lombard Odier Asset Management – 7.99% Carlton Holdings International – 7.28% Fidelity - 5.89% Ruffer LLP – 3.72% Unicorn Asset Management – 3.46% Mole Valley Asset Management – 3.01% As at 28th February 2019 the company has 115,835,037 ordinary shares of 10p each in issue. 32.3% of the ordinary shares of the Company are not held in public hands. and aviva below reporting threshold so if a persistent seller presumably them as all others the same mol
Businessweekly Awards 2019 Phoremost also shortlisted [link] mol
General Update re agm Have you seen the write up by Hardman and Co?
General Update re agm oops meant to add change of accounting ref date RNS 180119 Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents announces that it has changed its accounting reference date from 31 July to 31 December with immediate effect. As a result of the change of accounting reference date the Company’s reporting calendar will be as follows: Unaudited interim accounts for the 6 month period ended 31 January 2019 to be published by 30 April 2019. Publication of unaudited accounts for the 12 month period ended 31 July 2019 to be published by 31 October 2019 and publication of audited final accounts for the 17 month period ended 31 December 2019 to be published by 31 May 2020. Thereafter, interim and annual reports will be published each year for the 6 months to 30 June and 12 months to 31 December respectively, in accordance with the AIM Rules for Companies. [link] methinks due to timing of forecasted revenue flow - but perhaps not as publication of info in interim in line with aim rules ie within 3 months of end of relevant period anyway this company is usually either on time or ahead of aim rules in general mol
General Update re agm btw the two largest trades of the day on london stock exchange 14:40:24 30-Jan-2019 43.33 GBX 95,000 41,163.50 Off-book LRGS AIMX 14:37:11 30-Jan-2019 42.00 GBX 200,000 84,000.00 Off-book AIM mol
General Update re agm Proactiveinvestors UK Avacta's Alastair Smith encouraged by significant progress and share price... Alastair Smith, chief executive of Avacta Group PLC (LON:AVCT), caught up with Proactive London's Andrew Scott to talk through a business update released from the firm to coincide with its annual general meeting this week. slides re agm [link] and recent independent published paper MDPI Toxin Neutralization Using Alternative Binding Proteins Animal toxins present a major threat to human health worldwide, predominantly through snakebite envenomings, which are responsible for over 100,000 deaths each year. To date, the only available treatment against snakebite envenoming is plasma-derived... also very happy with improvement in sp - but not with my non-top decision at c 24p lol considering top up though at this level just thought i would also like to put avacta at top of discussion list tonight! mol mol